Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Clinical significance of serum tenascin-c levels in epithelial ovarian cancer.

Didem T, Faruk T, Senem K, Derya D, Murat S, Murat G, Oznur K.

Tumour Biol. 2014 Jul;35(7):6777-82. doi: 10.1007/s13277-014-1923-z.

PMID:
24722824
2.

Clinical significance of serum tenascin-C levels in breast cancer.

Tastekin D, Tas F, Karabulut S, Duranyildiz D, Serilmez M, Guveli M, Vatansever S.

Tumour Biol. 2014 Jul;35(7):6619-25. doi: 10.1007/s13277-014-1875-3.

PMID:
24696262
3.

Clinical significance of serum transforming growth factor-beta 1 (TGF-β1) levels in patients with epithelial ovarian cancer.

Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D.

Tumour Biol. 2014 Apr;35(4):3611-6. doi: 10.1007/s13277-013-1476-6.

PMID:
24310505
4.

Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients.

Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D.

Tumour Biol. 2014 Apr;35(4):3327-31. doi: 10.1007/s13277-013-1438-z.

PMID:
24272203
5.

Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer.

Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D.

Tumour Biol. 2014 Apr;35(4):3125-32. doi: 10.1007/s13277-013-1405-8.

PMID:
24254307
6.

Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer.

Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D.

Cancer Chemother Pharmacol. 2014 Mar;73(3):631-7. doi: 10.1007/s00280-014-2396-x.

PMID:
24477605
7.

Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37.

8.

A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer.

Yildiz I, Tas F, Kilic L, Sen F, Saip P, Eralp Y, Keskin S, Karabulut S, Ciftci R, Serilmez M, Yasasever V, Aydiner A.

Cancer Chemother Pharmacol. 2013 Aug;72(2):437-44. doi: 10.1007/s00280-013-2212-z.

PMID:
23801282
9.

Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer.

Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, Kulesza-Bronczyk B, Kinalski M, Terlikowski SJ.

Eur Cytokine Netw. 2013 Jul-Sep;24(3):106-13. doi: 10.1684/ecn.2013.0340.

10.

Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?

Karabulut S, Akşit E, Tas F, Ciftci R, Aydiner A, Yildiz I, Keskin S, Eralp Y, Yasasever CT, Vatansever S, Disci R, Saip P.

Tumour Biol. 2014 May;35(5):4323-9. doi: 10.1007/s13277-013-1567-4.

PMID:
24390664
11.

Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.

Paek J, Lee SH, Yim GW, Lee M, Kim YJ, Nam EJ, Kim SW, Kim YT.

Eur J Obstet Gynecol Reprod Biol. 2011 Oct;158(2):338-42. doi: 10.1016/j.ejogrb.2011.05.021.

PMID:
21683503
12.

Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer.

Tas F, Kilic L, Bilgin E, Keskin S, Sen F, Ciftci R, Yildiz I, Yasasever V.

Int J Gynecol Cancer. 2013 Feb;23(2):276-81. doi: 10.1097/IGC.0b013e31827b8796.

PMID:
23266651
13.

Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer.

Kolwijck E, Span PN, Thomas CM, Bulten J, Sweep FC, Massuger LF.

Oncol Rep. 2010 Feb;23(2):579-84.

PMID:
20043124
14.

Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer.

Kong SY, Han MH, Yoo HJ, Hwang JH, Lim MC, Seo SS, Yoo CW, Kim JH, Park SY, Kang S.

Ann Surg Oncol. 2012 May;19(5):1707-12. doi: 10.1245/s10434-011-1943-5.

PMID:
21833668
15.

Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer.

Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D.

Tumour Biol. 2014 Apr;35(4):3095-102. doi: 10.1007/s13277-013-1401-z.

PMID:
24307621
16.
17.

Pretreatment CA 15-3 levels do not predict disease-free survival in patients with advanced epithelial ovarian cancer.

Gemer O, Oustinov N, Gdalevich M, Dubnik S, Levy R, Yachnin A, Lavie O, Ben Baruch N, Ben Arie A.

Tumori. 2013 Mar-Apr;99(2):257-60. doi: 10.1700/1283.14201.

PMID:
23748823
18.

Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.

Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A.

Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2496-506. doi: 10.1158/1055-9965.EPI-11-0635.

19.

Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer.

Hong F, Li Y, Xu Y, Zhu L.

J Int Med Res. 2013 Feb;41(1):64-71. doi: 10.1177/0300060513475759.

PMID:
23569131
20.

Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer.

Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA.

Cancer. 1994 Apr 1;73(7):1882-8.

Items per page

Supplemental Content

Support Center